5-MeO-IsoqT
5-MeO-IsoqT, also known as 5-MeO-desethylisoquinuclidineT or as desethyl-17,18-secoibogaine, is a tryptamine derivative and a deconstructed and simplified analogue of ibogaine. It is a derivative of ibogaine lacking the tetrahydroazepine ring but with the isoquinuclidine ring retained. Similarly to ibogaine and noribogaine, but unlike structurally related tryptamines like 5-MeO-DMT and 5-MeO-pip-T, 5-MeO-IsoqT is said to have insignificant activity as an agonist of the serotonin 5-HT1A and 5-HT2A receptors. 5-MeO-IsoqT was described in the scientific literature by Dalibor Sames and colleagues in 2024. Other closely related isoquinuclidine-tryptamines have also been described by David E. Olson and colleagues in 2021, for instance the ethyl-conserved 5-hydroxy and 5-methoxy analogues.